Inobrodib is the first drug to target p300/CBP, a new way to treat specific cancers.  Following a successful Phase I campaign, new funding will be used to progress clinical development towards to pivotal registration trials. Cambridge, UK, 26 January 2022 – CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat […]